NOTCH4: A Protein Potential Drug Target (G4855)

Target Name: NOTCH4

NCBI ID: G4855

NOTCH4

NOTCH4: A Protein Potential Drug Target

NOTCH4 (NOTCH4 (ICD4)_HUMAN) is a protein that is expressed in various tissues of the human body, including the nervous system, endothelial cells, pericytes, and epithelial cells. It is a transmembrane protein that is characterized by the presence of a Notch1 extracellular domain and a Notch2 intracellular domain.

The Notch1 extracellular domain is a critical region that is involved in the formation of the Notch complex, a protein-protein interaction that is important for the development and maintenance of tissues. The Notch2 intracellular domain is responsible for the localization of the Notch1 protein to the endoplasmic reticulum, where it can be processed and then targeted to specific cellular processes.

NOTCH4 is involved in a variety of physiological processes in the body, including cell survival, growth, and differentiation. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of NOTCH4 is its potential as a drug target. The use of NOTCH4 as a drug target has been shown to be effective in treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, NOTCH4 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. Studies have shown that inhibiting NOTCH4 can be an effective way to treat these cancers, as it can inhibit the growth and survival of cancer cells.

In neurodegenerative diseases, NOTCH4 has been shown to be involved in the development and progression of diseases such as Alzheimer's disease and Parkinson's disease. Studies have shown that NOTCH4 levels are elevated in the brains of individuals with these conditions, and that inhibiting NOTCH4 can be an effective way to treat these diseases.

In autoimmune disorders, NOTCH4 has been shown to be involved in the development and progression of diseases such as rheumatoid arthritis and multiple sclerosis. Studies have shown that NOTCH4 levels are elevated in individuals with these conditions, and that inhibiting NOTCH4 can be an effective way to treat these disorders.

In conclusion, NOTCH4 is a protein that is expressed in various tissues of the human body and is involved in a variety of physiological processes in the body. Its potential as a drug target has been shown in a variety of studies, including its potential as a treatment for cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of NOTCH4 in these diseases and to develop effective treatments.

Protein Name: Notch Receptor 4

Functions: Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. May regulate branching morphogenesis in the developing vascular system (By similarity)

The "NOTCH4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NOTCH4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets